IO Biotech, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 26.18 million compared to USD 20.07 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.7 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.18 USD | -4.07% |
|
-9.92% | -37.23% |
May. 15 | HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating | MT |
May. 14 | IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.23% | 81.03M | |
+35.75% | 51.51B | |
-6.60% | 39.03B | |
+34.92% | 38.91B | |
-12.11% | 26.68B | |
+12.09% | 26.13B | |
-15.74% | 19.91B | |
+42.84% | 13.71B | |
+30.32% | 12.38B | |
-3.85% | 11.74B |
- Stock Market
- Equities
- IOBT Stock
- News IO Biotech, Inc.
- IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023